{"id":"ral-or-egv-based-arv-regimens-with-abc","safety":{"commonSideEffects":[{"rate":"10%","effect":"Nausea"},{"rate":"8%","effect":"Diarrhea"},{"rate":"6%","effect":"Fatigue"}]},"_chembl":{"chemblId":"CHEMBL2071405","moleculeType":"Small molecule","molecularWeight":"402.53"},"_dailymed":null,"mechanism":{"_ai_source":"groq-llama-8b","explanation":"Raltegravir (RAL) is an HIV-1 integrase strand transfer inhibitor (INSTI). It blocks the integration of viral DNA into the host cell genome, preventing viral replication.","oneSentence":"Inhibits HIV-1 integrase","_ai_confidence":"high"},"_scrapedAt":"2026-03-28T03:15:56.432Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"HIV-1 infection"}]},"trialDetails":[{"nctId":"NCT03327740","phase":"","title":"PRJ2203: Dolutegravir Post Authorization Safety Study (PASS)","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2014-09-30","conditions":"Infection, Human Immunodeficiency Virus I","enrollment":1}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":3379,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"phase_2","status":"active","brandName":"RAL or EGV based ARV regimens with ABC","genericName":"RAL or EGV based ARV regimens with ABC","companyName":"ViiV Healthcare","companyId":"viiv-healthcare","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Inhibits HIV-1 integrase Used for HIV-1 infection.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":1,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}